Alpharma works to fend off King

King Pharmaceuticals may be all fired up about the possibility of bringing Alpharma into its specialty-drug fold, but the feeling isn't mutual. And Alpharma isn't just saying no. It's working to hold King off. The company has adopted a shareholder rights plan designed to guard against a King takeover. If anyone acquires 15 percent or more of Alpharma's common stock--or launches a tender offer (hint, hint)--the rights will become exercisable.

But the plan isn't designed to head off every acquisition offer, CEO Dean Mitchell said in a statement. Just those whose terms aren't fair and "in the best interests of all Alpharma shareholders."

As you know, King offered $33 a share, or some $1.4 billion for Alpharma, but the company rebuffed that offer. King then went public with its bid in hopes of persuading Alpharma management, saying it was open to negotiation and preferred a friendly takeover. But Alpharma wasn't convinced.

So King filed with the FTC last week, saying it intends to buy a majority share in Alpharma. That's a clear signal of King's intent to pursue a tender offer anyway. Alpharma investors seem sure that King will come back with a higher offer; the stock closed at $37.50 on Friday.

- see Alpharma's release

Related Articles
Alpharma shares skyrocket on King's buyout offer
King offers $1.4B for Alpharma
Alpharma touts Phase III pain drug data
Alpharma sub inks $202M deal for pain drug
Alpharma to proceed with painkiller trial
Investors bid up Alpharma stock on rumors of a sale

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.